Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology (MRI-based Breast Biopsy, Ultrasound-based Breast Biopsy, Mammography-based (Stereotactic) Breast Biopsy, CT-based Breast Biopsy, Other Image Based Breast Biopsy), By End-use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Region, And By Segment Forecasts, 2024-2031.

Breast Cancer Core Needle Biopsy Market Size is valued at USD 697.3 Mn in 2023 and is predicted to reach USD 1,042.3 Mn by the year 2031 at a 5.34% CAGR during the forecast period for 2024-2031.

A biopsy is a confirmatory procedure that helps in early cancer/tumour diagnosis, resulting in faster recovery, higher survival rates, and lower rates of morbidity and mortality. A Breast Cancer Core Needle Biopsy is a less invasive alternative to surgical biopsies and can provide valuable information to guide treatment decisions. Medical practitioners recommend a breast biopsy for an early diagnosis of breast cancer. Many public and private organizations, businesses, and healthcare facilities are developing creative campaigns to increase public knowledge about breast cancer and the advantages of early detection for overall health. Raising breast cancer awareness was the initial goal of India's extensive Pink Chain Campaign. 

Furthermore, it is anticipated that rising R&D spending will promote market expansion. With the advent of highly advanced, minimally invasive breast biopsy technologies, hitherto unrealized business opportunities are expected to manifest. Moreover, rising global breast biopsy rates and an ageing female population 

Competitive Landscape

Some Major Key Players In The Breast Cancer Core Needle Biopsy Market:

• Intact Medical Corporation
• Ethicon Surgical Technologies.
• Galling SRL
• Leica Biosystems Nussle GmbH
• Hologic, Inc
• Argon Medical Devices
• Encapsule Medical Devices LLC.
• Cook Medical Incorporated
• Becton Dickinson and Company
• R. Bard, Inc.
• Zenalux Biomedical, Inc.,
• Hoffmann-La Roche Ltd.,
• OncoCyte Corporation,
• Laboratory Corporation of America Holdings (LabCorp),
• Scion Medical Technologies,
• Planmed Oy,
• Aurora Imaging Technology Inc.,
• Carestream Health,
• Cardinal Health,
• PerkinElmer
• QIAGEN
• Thermo Fisher Scientific
• Medtronic
• Danaher Corporation
• Others

Market Segmentation:

The breast cancer core needle biopsy market is segmented on the basis of Technology as well as End-Use. According to Technology, the market is segmented as MRI-based breast biopsy, ultrasound-based breast biopsy, mammography-based (stereotactic) breast biopsy, CT-based breast biopsy and other image-based breast biopsy. As per the End-Use, the market is segmented into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and academic & research institutes.

Based On Technology, The CT-Based Breast Biopsy Segment Is Accounted As A Major Contributor In The Breast Cancer Core Needle Biopsy Market. 

The cut-based breast biopsy category is expected to hold a major share of the global breast cancer core needle biopsy market in 2022. The increase in growth is ascribed to the expanding accessibility of Technology and the increasing technological breakthroughs in CT breast biopsy. Additionally, it is predicted that stepping up research and development efforts will help the industry thrive. It has also been demonstrated that FDG PET/CT and FES PET/CT can improve the diagnostic and therapeutic options for metastatic breast cancers. 

The Hospitals And Diagnostic Laboratories Segment Witness Growth At A Rapid Rate.

The Hospital and diagnostic laboratory segment are projected to grow at a rapid rate in the global breast cancer core needle biopsy market. A favourable environment for segment expansion is anticipated, given the rising number of patient visits to hospitals and the increased uptake of innovative tools and Technology in facilities. Collaboration between hospitals and diagnostic laboratories is vital for a seamless workflow in breast cancer core needle biopsy procedures. Timely communication and efficient sample processing contribute to faster diagnosis and treatment initiation. The integration of core needle biopsy services within these healthcare settings reflects the commitment to advancing diagnostic capabilities and improving patient outcomes in the realm of breast cancer care. 

In The Region, The North America Breast Cancer Core Needle Biopsy Market Holds A Significant Revenue Share.

The North American breast cancer core needle biopsy market is expected to hold the maximum market revenue share in the near future. The region's significant market leadership can be attributed to its sophisticated healthcare systems, vast research capacity, and targeted patient awareness campaigns. These factors all enhance the early detection and efficient treatment of breast cancer. Prominent diagnostic and medical facilities in the US and Canada have long emphasized the value of routine screenings.

In addition, Asia Pacific is estimated to grow at a rapid rate in the global Breast Cancer Core Needle Biopsy market. The integration of AI into diagnostic procedures is a crucial component of APAC's leadership in breast cancer core needle biopsy procedures. AI-powered technologies are being utilized throughout the region to help pathologists interpret biopsy data more precisely while minimizing subjectivity and potential errors. This technical development strengthens the region's dedication to creative solutions for improved healthcare outcomes while also improving diagnostic accuracy.

Recent Developments:

• In Jan 2021, Somatex Medical Technologies GmbH, a market leader in biopsy site markers and localization technologies, was acquired by Hologic, Inc. for an estimated $64 million, the company disclosed this morning. Hologic's approach to offering an all-encompassing collection of groundbreaking solutions spanning the entire spectrum of breast health care was reinforced by the transaction.

Breast Cancer Core Needle Biopsy Market Report Scope